Naltrexone controlled-release - Alkermes

Drug Profile

Naltrexone controlled-release - Alkermes

Alternative Names: ALKS 6428; Vivitrex; Vivitrol; XL-NTX; XR-NTX

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alkermes
  • Developer Alkermes; Alkermes plc; Cephalon; Cilag GmbH International
  • Class Analgesics; Cyclopropanes; Drug withdrawal therapies; Eye disorder therapies; Irritable bowel syndrome therapies; Morphinans; Small molecules
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alcoholism; Opioid abuse
  • No development reported Drug abuse

Most Recent Events

  • 30 Nov 2017 Alkermes completes a phase III trial for Opioid abuse (Combination therapy) in USA (PO) (NCT02696434)
  • 09 Jan 2017 Alkermes completes a phase III trial in Opioid abuse (Combination therapy) in USA (NCT02537574)
  • 01 Apr 2016 Alkermes initiates a phase III trial for Opioid abuse (Combination therapy) in USA (PO) (NCT02696434)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top